Comparative analysis of angiogenic gene expression in normal and impaired wound healing in diabetic mice: effects of extracorporeal shock wave therapy.
Impaired wound healing is a persistent clinical problem which has been treated with mixed results. Studies aimed at elucidating the mechanism of impaired wound healing have focused on small cohorts of genes which leave an incomplete picture of the wound healing process. We aimed to investigate impaired wound healing via a comprehensive panel of angiogenic/inflammation-related genes and wound closure kinetics with and without the application of extracorporeal shock wave therapy (ESWT), which has been demonstrated to improve wound healing. Full-thickness skin from the dorsal surface of "normal" (BALB/c) and "impaired" (db (+)/db (+)) mice was excised, and wound margin tissue was harvested 2, 7, and 10 days post injury. A separate, but identical wound model was established over 40 days in order to measure wound closure kinetics. Over time, the normal non-ESWT treated wounds exhibited varying patterns of elevated expression of 25-30 genes, whereas wounds with impaired healing displayed prolonged elevated expression of only a few genes (CXCL2, CXCL5, CSF3, MMP9, TGF-α). In response to ESWT, gene expression was augmented in both types of wounds, especially in the expression of PECAM-1; however, ESWT had no effect on wound closure in either model. In addition, multiple doses of ESWT exacerbated the delayed wound healing, and actually caused the wounds to initially increase in size. These data provide a more complete picture of impaired wound healing, and a way to evaluate various promising treatments.
Zins
Stephen R
SR
Regenerative Medicine Department, Operational and Undersea Medicine Directorate, Naval Medical Research Center, Room 2W06, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Amare
Mihret F
MF
Tadaki
Douglas K
DK
Elster
Eric A
EA
Davis
Thomas A
TA
D042501:Angiogenic Proteins / Q000032:analysis / Q000235:genetics*; D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000235:genetics* / Q000503:physiopathology / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000235:genetics* / Q000503:physiopathology; D005260:Female; D015870:Gene Expression / Q000528:radiation effects; D020869:Gene Expression Profiling; D019220:High-Energy Shock Waves / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D016688:Mice, Inbred NOD; D008822:Mice, Transgenic; D018919:Neovascularization, Physiologic / Q000235:genetics*; D012867:Skin / Q000293:injuries / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D014945:Wound Healing / Q000235:genetics* / Q000502:physiology / Q000528:radiation effects
D042501:Angiogenic Proteins